Treatment of primary progressive multiple sclerosis

Area of Science:

• Neuroimmunology
• Neurodegeneration
• Multiple Sclerosis Pathophysiology

Background:

• Primary progressive multiple sclerosis (MS) is a neurodegenerative phenotype.
• Characterized by progressive disability rather than relapses.
• Current immunomodulatory treatments have limited efficacy in primary progressive MS.

Purpose of the Study:

• To review the challenges and future directions in managing primary progressive MS.
• To highlight the limited impact of current therapies on disability progression.
• To explore potential therapeutic strategies and preventive measures.

Main Methods:

• Review of existing literature on primary progressive MS.
• Analysis of treatment outcomes for immunomodulatory and immunosuppressive therapies.
• Discussion of emerging remyelinating and regenerative strategies.
• Consideration of preventive measures based on secondary progressive MS studies.

Main Results:

• Immunomodulatory and immunosuppressive therapies show minimal impact on disability progression in primary progressive MS.
• Symptomatic treatments can improve quality of life.
• Remyelinating and regenerative strategies are promising future directions.
• Eliminating tobacco smoking may delay the onset of progressive MS.

Conclusions:

• Primary progressive MS requires novel therapeutic approaches beyond current immunomodulatory strategies.
• Focus should shift towards neuroprotection, remyelination, and regeneration.
• Preventive strategies, such as smoking cessation, may play a role in delaying disease onset.